SRR12202488
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.350
- SPERMATOGENESIS+0.300
- KRAS_SIGNALING_DN+0.290
- APICAL_SURFACE+0.120
- HEDGEHOG_SIGNALING+0.030
- MYOGENESIS+0.030
- ANGIOGENESIS+0.020
- MYC_TARGETS_V2+0.000
- G2M_CHECKPOINT-0.070
- E2F_TARGETS-0.140
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.510
- INTERFERON_ALPHA_RESPONSE-0.480
- ANDROGEN_RESPONSE-0.450
- COMPLEMENT-0.440
- IL2_STAT5_SIGNALING-0.430
- IL6_JAK_STAT3_SIGNALING-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- APOPTOSIS-0.400
- ALLOGRAFT_REJECTION-0.390
- OXIDATIVE_PHOSPHORYLATION-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-21-5782-01A-01R-1635-07 | — | cohortSC | 0.936 |
| 2 | SRR650150 | — | — | 0.927 |
| 3 | SRR1797291 | — | cohortSC | 0.923 |
| 4 | SRR12696788 | — | — | 0.923 |
| 5 | MNG459 | — | — | 0.919 |
| 6 | SRR1336379 | GTEX | — | 0.919 |
| 7 | SRR4195643 | — | — | 0.919 |
| 8 | ERR4976605 | — | D | 0.918 |
| 9 | SRR12696783 | — | — | 0.917 |
| 10 | SRR4195695 | — | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |